Scaling and superscaling solutions from the functional renormalization group

We study the renormalization group flow of $\mathbb{Z}_2$-invariant supersymmetric and non-supersymmetric scalar models in the local potential approximation using functional renormalization group methods. We focus our attention to the fixed points of the renormalization group flow of these models, which emerge as scaling solutions. In two dimensions these solutions are interpreted as the minimal (supersymmetric) models of conformal field theory, while in three dimension they are manifestations of the Wilson-Fisher universality class and its supersymmetric counterpart. We also study the analytically continued flow in fractal dimensions between 2 and 4 and determine the critical dimensions for which irrelevant operators become relevant and change the universality class of the scaling solution. We also include novel analytic and numerical investigations of the properties that determine the occurrence of the scaling solutions within the method. For each solution we offer new techniques to compute the spectrum of the deformations and obtain the corresponding critical exponents.Comment: 23 pages, 14 figures; v2: several improvements, new references, version to appear in PR

A functional perspective on emergent supersymmetry

We investigate the emergence of ${\cal N}=1$ supersymmetry in the long-range behavior of three-dimensional parity-symmetric Yukawa systems. We discuss a renormalization approach that manifestly preserves supersymmetry whenever such symmetry is realized, and use it to prove that supersymmetry-breaking operators are irrelevant, thus proving that such operators are suppressed in the infrared. All our findings are illustrated with the aid of the $\epsilon$-expansion and a functional variant of perturbation theory, but we provide numerical estimates of critical exponents that are based on the non-perturbative functional renormalization group.Comment: 28 pages, 2 figures; v2: published version, includes a new appendi

Convergence of Derivative Expansion in Supersymmetric Functional RG Flows

We confirm the convergence of the derivative expansion in two supersymmetric models via the functional renormalization group method. Using pseudo-spectral methods, high-accuracy results for the lowest energies in supersymmetric quantum mechanics and a detailed description of the supersymmetric analogue of the Wilson-Fisher fixed point of the three-dimensional Wess-Zumino model are obtained. The superscaling relation proposed earlier, relating the relevant critical exponent to the anomalous dimension, is shown to be valid to all orders in the supercovariant derivative expansion and for all $d \ge 2$

Treating supersymmetric systems with the functional renormalization group

Supersymmetrie ist eine Theorie die fortwährendes Interesse auf sich zieht. Aus diesem Grund wird im Rahmen dieser Arbeit die funktionale Renormierungsgruppe (FRG) verwendet um aus diesem Blickwinkel Einblicke zu gewinnen. Die Arbeit ist zweigeteilt: Im ersten Abschnitt diskutieren wir technische Aspekte und untersuchen die Anwendbarkeit von Techniken bekannt aus bosonischen Theorien. Wir befassen uns mit supersymmetrischer Quantenmechanik und diskutieren in diesem Rahmen die Ableitungsentwicklung. Des Weiteren wird der Unterschied zwischen supersymmetrischen Flussgleichungen in der symmetrischen und spontan gebrochenen Phasen herausgearbeitet. Danach wenden wir uns den Wess-Zumino Modellen in zwei und drei Raumzeit Dimensionen zu. Wir verwenden ein Schießverfahren um die Fixpunktlösungen zu bestimmen. Zusätzlich beschreiben wir, wie eine polynomielle Entwicklung um den Ursprung es erlaubt, den Ising Fixpunkt zu finden. Wir geben die Spektren der Fixpunkte und untersuchen den Einfluss verschiedener Implementierungen der Variation der anomalen Dimension. Im zweiten Abschnitt wenden wir uns experimentell physikalisch relevanteren Themen zu. Wir starten mit emergenter Supersymmetrie. Eine Yukawa Theorie wird umformuliert und, mittels der Techniken bekannt von den supersymmetrischen Theorien, das Auftauchen der Supersymmetrie gezeigt. Es zeigt sich, dass das Spektrum der Theorie aus einem supersymmetrischen und einem explizit Supersymmetrie brechenden Teil besteht. Wir sehen dies, so lange der Fixpunkt Kopplungen aufweist, die Supersymmetrie erlauben. Abschließend betrachten wir das supersymmetrische O(N) Model in drei Raumzeit Dimensionen. Wir zeigen mittels polynomieller und Schieß-Verfahren, dass kein globaler Fixpunkt existiert. Die Ergebnisse werden bis zur LPA’ (lokale Potenzial Approximation) Trunkierung gegeben. Wir beleuchten diese Ergebnisse mit Hinblick auf die kritische Dimension des Models

3-D Printed Protective Equipment during COVID-19 Pandemic

While the number of coronavirus cases from 2019 continues to grow, hospitals are reporting shortages of personal protective equipment (PPE) for frontline healthcare workers. Furthermore, PPE for the eyes and mouth, such as face shields, allow for additional protection when working with aerosols. 3-D printing enables the easy and rapid production of lightweight plastic frameworks based on open-source data. The practicality and clinical suitability of four face shields printed using a fused deposition modeling printer were examined. The weight, printing time, and required tools for assembly were evaluated. To assess the clinical suitability, each face shield was worn for one hour by 10 clinicians and rated using a visual analogue scale. The filament weight (21-42 g) and printing time (1:40-3:17 h) differed significantly between the four frames. Likewise, the fit, wearing comfort, space for additional PPE, and protection varied between the designs. For clinical suitability, a chosen design should allow sufficient space for goggles and N95 respirators as well as maximum coverage of the facial area. Consequently, two datasets are recommended. For the final selection of the ideal dataset to be used for printing, scalability and economic efficiency need to be carefully balanced with an acceptable degree of protection

Step-wise assembly, maturation and dynamic behavior of the human CENP-P/O/R/Q/U kinetochore sub-complex

Kinetochores are multi-protein megadalton assemblies that are required for attachment of microtubules to centromeres and, in turn, the segregation of chromosomes in mitosis. Kinetochore assembly is a cell cycle regulated multi-step process. The initial step occurs during interphase and involves loading of the 15-subunit constitutive centromere associated complex (CCAN), which contains a 5-subunit (CENP-P/O/R/Q/U) sub-complex. Here we show using a fluorescent three-hybrid (F3H) assay and fluorescence resonance energy transfer (FRET) in living mammalian cells that CENP-P/O/R/Q/U subunits exist in a tightly packed arrangement that involves multifold protein-protein interactions. This sub-complex is, however, not pre-assembled in the cytoplasm, but rather assembled on kinetochores through the step-wise recruitment of CENP-O/P heterodimers and the CENP-P, -O, -R, -Q and -U single protein units. SNAP-tag experiments and immuno-staining indicate that these loading events occur during S-phase in a manner similar to the nucleosome binding components of the CCAN, CENP-T/W/N. Furthermore, CENP-P/O/R/Q/U binding to the CCAN is largely mediated through interactions with the CENP-N binding protein CENP-L as well as CENP-K. Once assembled, CENP-P/O/R/Q/U exchanges slowly with the free nucleoplasmic pool indicating a low off-rate for individual CENP-P/O/R/Q/U subunits. Surprisingly, we then find that during late S-phase, following the kinetochore-binding step, both CENP-Q and -U but not -R undergo oligomerization. We propose that CENP-P/O/R/Q/U self-assembles on kinetochores with varying stoichiometry and undergoes a pre-mitotic maturation step that could be important for kinetochores switching into the correct conformation necessary for microtubule-attachment

Interleukin-6 receptor blockade in treatment-refractory MOG-IgG–associated disease and neuromyelitis optica spectrum disorders

BACKGROUND AND OBJECTIVES: To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–IgG–associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD). METHODS: Annualized relapse rate (ARR), Expanded Disability Status Scale score, MRI, autoantibody titers, pain, and adverse events were retrospectively evaluated in 57 patients with MOGAD (n = 14), aquaporin-4 (AQP4)-IgG seropositive (n = 36), and seronegative NMOSD (n = 7; 12%), switched to TCZ from previous immunotherapies, particularly rituximab. RESULTS: Patients received TCZ for 23.8 months (median; interquartile range 13.0–51.1 months), with an IV dose of 8.0 mg/kg (median; range 6–12 mg/kg) every 31.6 days (mean; range 26–44 days). For MOGAD, the median ARR decreased from 1.75 (range 0.5–5) to 0 (range 0–0.9; p = 0.0011) under TCZ. A similar effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0–5] to 0 [range 0–4.2]; p < 0.001) and for seronegative NMOSD (from 3.0 [range 1.0–3.0] to 0.2 [range 0–2.0]; p = 0.031). During TCZ, 60% of all patients were relapse free (79% for MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI inflammatory activity decreased in MOGAD (p = 0.04; for the brain) and in AQP4-IgG+ NMOSD (p < 0.001; for the spinal cord). Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (n = 44), ARR reductions were confirmed, including the subgroups of MOGAD (n = 11) and AQP4-IgG+ patients (n = 28). Similarly, in the group of patients treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40% for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no advantage compared with TCZ monotherapy. DISCUSSION: This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research

Covid-19 triage in the emergency department 2.0: how analytics and AI transform a human-made algorithm for the prediction of clinical pathways

The Covid-19 pandemic has pushed many hospitals to their capacity limits. Therefore, a triage of patients has been discussed controversially primarily through an ethical perspective. The term triage contains many aspects such as urgency of treatment, severity of the disease and pre-existing conditions, access to critical care, or the classification of patients regarding subsequent clinical pathways starting from the emergency department. The determination of the pathways is important not only for patient care, but also for capacity planning in hospitals. We examine the performance of a human-made triage algorithm for clinical pathways which is considered a guideline for emergency departments in Germany based on a large multicenter dataset with over 4,000 European Covid-19 patients from the LEOSS registry. We find an accuracy of 28 percent and approximately 15 percent sensitivity for the ward class. The results serve as a benchmark for our extensions including an additional category of palliative care as a new label, analytics, AI, XAI, and interactive techniques. We find significant potential of analytics and AI in Covid-19 triage regarding accuracy, sensitivity, and other performance metrics whilst our interactive human-AI algorithm shows superior performance with approximately 73 percent accuracy and up to 76 percent sensitivity. The results are independent of the data preparation process regarding the imputation of missing values or grouping of comorbidities. In addition, we find that the consideration of an additional label palliative care does not improve the results

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. METHODS: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). RESULTS: Seropositive patients were found to be predominantly female (p 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. CONCLUSION: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients